DK0845007T3 - Farmaceutisk præparat indeholdende interferon-gamma hæmmere - Google Patents

Farmaceutisk præparat indeholdende interferon-gamma hæmmere

Info

Publication number
DK0845007T3
DK0845007T3 DK96927141T DK96927141T DK0845007T3 DK 0845007 T3 DK0845007 T3 DK 0845007T3 DK 96927141 T DK96927141 T DK 96927141T DK 96927141 T DK96927141 T DK 96927141T DK 0845007 T3 DK0845007 T3 DK 0845007T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical preparation
preparation containing
containing interferon
gamma inhibitors
gamma
Prior art date
Application number
DK96927141T
Other languages
Danish (da)
English (en)
Inventor
William James Ferguson Mark
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Application granted granted Critical
Publication of DK0845007T3 publication Critical patent/DK0845007T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/249—Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
DK96927141T 1995-08-18 1996-08-09 Farmaceutisk præparat indeholdende interferon-gamma hæmmere DK0845007T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9516967A GB2304342A (en) 1995-08-18 1995-08-18 Pharmaceutical comprising either an inhibitor or a stimulator of interferon gamma
PCT/GB1996/001949 WO1997007136A2 (fr) 1995-08-18 1996-08-09 Composition pharmaceutique contenant des inhibiteurs de l'inteferon gamma

Publications (1)

Publication Number Publication Date
DK0845007T3 true DK0845007T3 (da) 2001-12-17

Family

ID=10779448

Family Applications (2)

Application Number Title Priority Date Filing Date
DK96927141T DK0845007T3 (da) 1995-08-18 1996-08-09 Farmaceutisk præparat indeholdende interferon-gamma hæmmere
DK99202497T DK0972521T3 (da) 1995-08-18 1996-08-09 Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK99202497T DK0972521T3 (da) 1995-08-18 1996-08-09 Farmaceutisk præparat, der indeholder interferon-gamma-stimulatorer

Country Status (12)

Country Link
EP (2) EP0972521B1 (fr)
JP (2) JP4070809B2 (fr)
AT (2) ATE208402T1 (fr)
AU (1) AU713809B2 (fr)
CA (1) CA2229590C (fr)
DE (2) DE69616803T2 (fr)
DK (2) DK0845007T3 (fr)
ES (2) ES2164911T3 (fr)
GB (1) GB2304342A (fr)
PT (2) PT972521E (fr)
WO (1) WO1997007136A2 (fr)
ZA (1) ZA966953B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1336654A1 (fr) 1998-12-09 2003-08-20 Protein Design Labs, Inc. Méthode de traitement du psoriasis utilisant un anticorps anti-interféron gamma
US6710025B1 (en) 1999-05-26 2004-03-23 The Brigham And Women's Hospital, Inc. Treatment of damaged tissue using agents that modulate the activity of alpha-smooth muscle actin
WO2000071148A2 (fr) * 1999-05-26 2000-11-30 The Brigham And Women's Hospital, Inc. Utilisations therapeutiques d'agents modulant l'activite de l'actine alpha de muscle lisse
US10080779B2 (en) 2004-12-15 2018-09-25 Universite D'angers Method for increasing the expression of anti-microbial peptides by keratinocytes comprising administering a composition comprising IL-17, TNF-alpha and OSM
WO2008099829A1 (fr) * 2007-02-14 2008-08-21 Japan Science And Technology Agency Procédé de formation d'adhésion intestinale chez un animal expérimental, procédé de production d'animal expérimental présentant une adhésion intestinale, procédé de criblage d'agent de prévention d'adhérence intestinale, et agent de p
GB0724231D0 (en) * 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
RU2539383C1 (ru) * 2013-11-29 2015-01-20 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Фармацевтическая композиция для лечения трофических язв и длительно незаживающих ран различной этиологии в виде мази

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL78444A (en) * 1986-04-08 1992-05-25 Yeda Res & Dev Human gamma interferon-specific receptor protein,antibody against said protein,and compositions containing said protein and antibody
JPH01502980A (ja) * 1986-06-17 1989-10-12 レイチ，スティーブン　デー ガンマインターフェロンと抗炎症剤または抗発熱剤との組合せ並びに疾患処置方法
NL8700927A (nl) * 1987-04-16 1988-11-16 Stichting Rega V Z W Anti-interferon-gamma-antilichamen; en hun therapeutische toepassing.
CA1335792C (fr) * 1987-08-18 1995-06-06 Chaim O. Jacob Methode et forme posologique utilisant un antagoniste de l'interferon gamma pour lutter contre les maladies auto-immunes associees au cmh
AU2855189A (en) * 1988-01-25 1989-07-27 Baker Cummins Dermatologicals, Inc. Method of treating fibrotic disorders
IL88378A (en) * 1988-11-14 2000-11-21 Yeda Res & Dev Human interferon-gamma binding proteins their manufacture and pharmaceutical compositions comprising them
ES2096553T3 (es) * 1988-12-19 1997-03-16 American Cyanamid Co Metodo para el tratamiento de choque endotoxico en un animal mamifero.
GB8905400D0 (en) * 1989-03-09 1989-04-19 Jonker Margreet Medicaments
ATE132191T1 (de) * 1989-04-19 1996-01-15 Hoffmann La Roche Auflösbare interferon-gamma-rezeptoren sowie verfahren zu deren herstellung
IT1231727B (it) * 1989-08-11 1991-12-21 Enrico Savoldi Peptidi utili per la determinazione e la purificazione di anticorpi anti gamma interferone.
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
CA2092541A1 (fr) * 1990-09-27 1992-03-28 Gail F. Seelig Antagonistes de l'interferon gamma humain
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
NL9101290A (nl) * 1991-07-23 1993-02-16 Stichting Rega V Z W Recombinant dna-molecuul voor de expressie van een fv-fragment van een antilichaam.
DE4234380A1 (de) * 1992-10-06 1994-04-07 Schering Ag Verwendung von Dopaminagonisten zur Aktivierung des gamma-Interferon-Produktion
EP0668873A1 (fr) * 1992-11-20 1995-08-30 Schering Corporation Antagonistes contre le gamma-interferon humain
US6558661B1 (en) * 1992-12-29 2003-05-06 Genentech, Inc. Treatment of inflammatory bowel disease with IFN-γ inhibitors
WO1995016036A2 (fr) * 1993-12-09 1995-06-15 Michel Aguet CHAINE β DE RECEPTEURS D'IFN-η ET LEURS DERIVES

Also Published As

Publication number Publication date
JP4070809B2 (ja) 2008-04-02
PT845007E (pt) 2002-03-28
ZA966953B (en) 1998-02-16
EP0845007A2 (fr) 1998-06-03
DE69616803D1 (de) 2001-12-13
DE69616803T2 (de) 2002-06-20
DE69626050D1 (de) 2003-03-06
AU6707196A (en) 1997-03-12
CA2229590A1 (fr) 1997-02-27
ATE208402T1 (de) 2001-11-15
JP2007119497A (ja) 2007-05-17
ES2192018T3 (es) 2003-09-16
EP0972521B1 (fr) 2003-01-29
WO1997007136A2 (fr) 1997-02-27
JP4616291B2 (ja) 2011-01-19
AU713809B2 (en) 1999-12-09
ES2164911T3 (es) 2002-03-01
ATE231728T1 (de) 2003-02-15
DE69626050T2 (de) 2004-01-22
GB9516967D0 (en) 1995-10-18
HK1023516A1 (en) 2000-09-15
CA2229590C (fr) 2010-10-12
EP0845007B1 (fr) 2001-11-07
JPH11511160A (ja) 1999-09-28
DK0972521T3 (da) 2003-05-05
GB2304342A (en) 1997-03-19
EP0972521A1 (fr) 2000-01-19
PT972521E (pt) 2003-06-30
WO1997007136A3 (fr) 1997-08-21

Similar Documents

Publication Publication Date Title
DE60018100D1 (en) Polymorphe form von atorvastatin-calcium
AP2001002187A0 (en) Piperidines as CCR5 modulators.
PT863891E (pt) (metilsulfonil)fenil-2-(5h)furanonas como inibidores de cox-2
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
FI973039A7 (fi) Uusia farnesyylitransferaasin inhibiittoreita, niiden valmistus ja niitä sisältäviä farmaseuttisia koostumuksia
FI973279A0 (fi) Uudet farnesyylitransferaasin inhibiittorit, niiden valmistus ja niitä sisältävät farmaseuttiset koostumukset
PT705100E (pt) Guanidinas substituidas terapeuticas
NZ240230A (en) Mercaptoacetylamide derivatives; preparation, use and pharmaceutical compositions thereof
PT1042305E (pt) Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
AU7486081A (en) Pharmaceutical compositions using amino acids for promoting healing of wounds
DK0845007T3 (da) Farmaceutisk præparat indeholdende interferon-gamma hæmmere
ATE253940T1 (de) Stabile lösung von calcitriol zum verpacken in phiolen
ZA886097B (en) Pharmaceutical composition for the treatment of psoriasis
ATE235245T1 (de) Pharmaceutische komposition
IT8821634A0 (it) Composizioni farmaceutiche che favoriscono la cicatrizzazione di ferite e procedimento per prepararle
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
ITMI932189A0 (it) Composizioni farmaceutiche contenenti n-acetilcarnosina per il trattamento della cataratta
IL111805A0 (en) Pharmaceutical compositions comprising dimeticone for the treatment of aphthae
IT1265647B1 (it) Composizione farmaceutiche topiche per le allergie respiratorie
DK0425109T3 (da) 3-substitueret-2-oxindolderivater som inhibitorer for interleukin-1-biosyntese
ATE338541T1 (de) Labdan-enthaltende arzneiformulierungen zur behandlung von tumoren oder leukämien
ECSP993296A (es) Moduladores de ccr5
ECSP993298A (es) Moduladores de ccr5